While the push to get Americans vaccinated continues across the country, preliminary data has emerged that lab-created monoclonal antibodies could be a treatment for COVID-19.
Worldwide, the number of potential pathogens is very large, while the resources for disease research and development (R&D) is limited. To ensure efforts under WHO’s R&D Blueprint are focused and productive, a list of diseases and pathogens are prioritized for R&D in public health emergency contexts.
